BRCA Gene – PharmaLive

AstraZeneca, Merck score win with Lynparza approval

Advanced pancreatic cancer, Blockbusters, BRCA Gene, BRCA mutation, FDA, FDA/Regulatory, New Indications, PARP Inhibitors

AstraZeneca and Merck’s ovarian cancer drug Lynparza received U.S. regulatory approval for the treatment of advanced pancreatic cancer.

December 30, 2019/by Reuters Health

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Advanced pancreatic cancer, Analysts, Approvals, BRCA Gene, BRCA mutation, BRCA-Mutated Ovarian Cancer, European Commission, FDA/Regulatory, Future Blockbusters, Ovarian Cancer, PARP Inhibitors

Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.

June 18, 2019/by Reuters Health

Top 10 Pipelines To Watch: 2019 Annual Report

Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, BRCA Gene, BRCA mutation, Breakthrough Therapy Designation, Business, Cancer, CAR-T Therapy, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, RNA Interference (RNAi), Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare Diseases

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

February 13, 2019/by Andrew Humphreys

FDA approves expanded use of AstraZeneca drug

BRCA Gene, BRCA mutation, Collaboration, Expanded Use, FDA/Regulatory, Genes, PARP Inhibitors

The U.S. Food and Drug Administration approved expanded use of AstraZeneca Plc’s cancer drug Lynparza.

January 12, 2018/by Reuters Health